Fintel reports that on December 22, 2023, Capital One initiated coverage of GlycoMimetics (NasdaqGM:GLYC) with a Overweight recommendation.
Analyst Price Forecast Suggests 120.87% Upside
As of December 16, 2023, the average one-year price target for GlycoMimetics is 5.61. The forecasts range from a low of 3.03 to a high of $8.40. The average price target represents an increase of 120.87% from its latest reported closing price of 2.54.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for GlycoMimetics is 0MM, a decrease of NaN%. The projected annual non-GAAP EPS is -0.67.
What is the Fund Sentiment?
There are 77 funds or institutions reporting positions in GlycoMimetics. This is a decrease of 4 owner(s) or 4.94% in the last quarter. Average portfolio weight of all funds dedicated to GLYC is 0.03%, an increase of 2.85%. Total shares owned by institutions decreased in the last three months by 2.15% to 35,513K shares. 
The put/call ratio of GLYC is 0.03, indicating a bullish outlook.
What are Other Shareholders Doing?
Bvf holds 9,544K shares representing 14.82% ownership of the company. No change in the last quarter.
Artal Group holds 8,589K shares representing 13.34% ownership of the company. No change in the last quarter.
NEA Management Company holds 4,764K shares representing 7.40% ownership of the company. No change in the last quarter.
Octagon Capital Advisors holds 3,000K shares representing 4.66% ownership of the company. No change in the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,662K shares representing 2.58% ownership of the company. In it's prior filing, the firm reported owning 1,581K shares, representing an increase of 4.86%. The firm decreased its portfolio allocation in GLYC by 5.95% over the last quarter.
GlycoMimetics Background Information
(This description is provided by the company.)
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has an ongoing Phase 1b clinical trial evaluating GMI-1359, a combined CXCR4 and E-selectin antagonist, also a wholly-owned drug candidate. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
